USFDA Warning Letter for Nacharam formulation facility

Regulatory & Legal View source PDF Explain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.7%Reaction day

₹380.45

prior close

₹371.65

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.8%-4.4% vs market

Pharmaceuticals peers, median of 155sector+0.2%-3.9% vs sector

On the reaction day the stock moved 4.4 pts less than Nifty Smallcap 250 and 3.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

+0.1

15m

+0.6

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.7+0.8-4.4+0.2-3.9

Next day

-6.4-0.3-6.2-0.4-6.1

-10.9-0.6-10.3-1.1-9.8

-8.8+1.9-10.7+0.7-9.5

-7.3+2.4-9.8+1.3-8.7

-6.6+2.6-9.2+1.5-8.1

-18.0+0.2-18.2+0.3-18.3

15d

-18.8+0.5-19.3-2.3-16.6

-21.9-4.5-17.5-5.1-16.9

-19.7-6.8-12.9-7.9-11.8

+22.7+5.8+16.9+0.7+22.0

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cohance Lifesciences has received a USFDA Warning Letter for its Nacharam formulation facility (FDF Unit-I) in Hyderabad, following an inspection conducted from August 4 to 12, 2025. The facility was previously classified as Official Action Indicated (OAI). The company notes that US revenues from this facility contributed less than 2% of consolidated revenues in FY2025, with related EBITDA contribution below 1%, indicating no material financial impact.

Likely market impact

Limited near-term financial impact due to low revenue contribution from this facility, but regulatory overhang may persist until concerns are resolved with USFDA.